Cephalexin Dosing for Adults and Pediatric Patients
For adults with skin and soft tissue infections like carbuncles caused by methicillin-susceptible Staphylococcus aureus (MSSA), cephalexin should be dosed at 500 mg four times daily (QID) orally, and for pediatric patients, 25-50 mg/kg/day divided into 4 doses. 1, 2
Adult Dosing
The IDSA guidelines and FDA labeling provide clear dosing parameters:
- Standard dose: 500 mg QID (four times daily) for MSSA skin and soft tissue infections 1
- Alternative dosing: 500 mg every 12 hours may be used for uncomplicated skin infections, though QID dosing is preferred for carbuncles 2
- Dosing range: Total daily dose ranges from 1-4 grams divided throughout the day 2
- Duration: Typically 7-10 days depending on clinical response 1
Important caveat: For penicillin-allergic patients, cephalexin is appropriate except in those with immediate hypersensitivity reactions (anaphylaxis, urticaria) 1
Pediatric Dosing
For children with skin and soft tissue infections:
- Standard dose: 25-50 mg/kg/day divided into 4 doses (QID) 1, 2
- Alternative dosing: The total daily dose may be divided and given every 12 hours (BID) for streptococcal pharyngitis and skin infections in children over 1 year 2
- Severe infections: Dosage may be doubled 2
Practical Pediatric Dosing Examples (QID):
- 10 kg child: 125 mg/5 mL suspension, ½ to 1 teaspoon QID
- 20 kg child: 125 mg/5 mL suspension, 1 to 2 teaspoons QID
- 40 kg child: 125 mg/5 mL suspension, 2 to 4 teaspoons QID 2
Emerging Evidence on Reduced Frequency Dosing
Recent high-quality pediatric studies suggest less frequent dosing may be effective:
Three times daily (TID): A 2025 Australian study of 149 children with bone and joint infections found that 45 mg/kg/dose (maximum 1.5 g) TID achieved 99% cure rates with good tolerability 3. This represents the most recent evidence supporting reduced frequency dosing.
Twice daily (BID): A 2024 PK/PD study demonstrated that cephalexin 25 mg/kg/dose (maximum 750 mg) TID or higher doses BID can achieve appropriate pharmacodynamic targets for MSSA 4
However, these reduced-frequency regimens are not yet incorporated into FDA labeling or IDSA guidelines, so QID dosing remains the standard of care, particularly for serious infections like carbuncles 1, 2.
Key Clinical Considerations
For carbuncles specifically: These purulent skin infections often require incision and drainage as the primary intervention. Antibiotics are indicated when there are systemic signs of infection (fever, tachycardia), failed initial treatment, or immunocompromised status 1. The 500 mg QID adult dose and 25-50 mg/kg/day pediatric dose are appropriate for MSSA coverage.
Common pitfall: Underdosing in heavier children. Pediatric dosing errors are common, with 32% of prescriptions being discordant with guidelines in one recent study 5. Children weighing over 20 kg are at highest risk for inappropriate dosing.
Renal adjustment: Cephalexin is substantially excreted by the kidney; dose adjustment may be needed in renal impairment, particularly in elderly patients 2
Drug interaction: Cephalexin increases metformin levels by 24-34%; careful monitoring is warranted when co-administered 2